Draft PRODUCT INFORMATION - Medsafe
140416 NEXAVAR data sheet Page 2 of 25 xenografts, in nude mice. Inhibition of tumour growth was accompanied by a reduction in tumour angiogenesis.
Download Draft PRODUCT INFORMATION - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEXAVAR safely and effectively. See full prescribing information for NEXAVAR.
Benefit Funds Newsletter New York State Teamsters
nytfund.orgNew York State Teamsters Benefit Funds Newsletter HOT TOPIC Spring 2009 News and information from your Trustees and Staff Over the past six years, the Health & Hospital Fund has experienced double digit
Prior Authorization Program Information - Florida …
www.bcbsfl.com* Important information on page 1 Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association Prior Authorization Program Information
新藥簡介：Nexavar、Eraxis、Aloxi - tma.tw
www.tma.tw醫 學 廣 場 38 2009, Vol.52, No.4 前 言 依據藥事法第39條的規定，製造、輸入藥品須申 請查驗登記，經核准發給藥品許可證後，始得為之。
PA Criteria - Universal American Medicare
www.universal-american-medicare.comUpdated 10/01/2018 2 Prior Authorization Group ADEMPAS Drug Names ADEMPAS Covered Uses All FDA-approved indications not otherwise excluded from Part D. Exclusion Criteria Required Medical Information For pulmonary arterial hypertension (PAH) (WHO Group 1): PAH was confirmed by right heart catheterization.
A list of medications that may lower your patients’ …
www.walgreenshealth.comINTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically